,24 Specifically, a residue-centric patient MHC presentation score (termed the Patient Harmonic-mean Best Rank [PHBR] score) that describes a person’s ability to present specific cancer mutations to T cells given their patient-specific HLA alleles (with lower PHBR indicating more efficient presentation) has been developed for MHC class-I and class-II. This evidence concerns the gene HLA-C and cancer.